Zacks Research Issues Pessimistic Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.93. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2027 earnings at $7.49 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

A number of other equities analysts have also issued reports on the company. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Up 2.0 %

Halozyme Therapeutics stock opened at $62.27 on Thursday. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32. The company’s 50-day moving average price is $56.76 and its two-hundred day moving average price is $54.76. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $29,000. Smartleaf Asset Management LLC raised its stake in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.